Cargando…

Modified hollow mesoporous silica nanoparticles as immune adjuvant-nanocarriers for photodynamically enhanced cancer immunotherapy

Nanomedicine has demonstrated great potential in enhancing cancer immunotherapy. However, nanoparticle (NP)-based immunotherapy still has limitations in inducing effective antitumor responses and inhibiting tumor metastasis. Herein, polyethylenimine (PEI) hybrid thin shell hollow mesoporous silica N...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qianru, Liu, Qianqian, Li, Heli, Dong, Liyun, Zhou, Yajie, Zhu, Jintao, Yang, Liu, Tao, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592702/
https://www.ncbi.nlm.nih.gov/pubmed/36304892
http://dx.doi.org/10.3389/fbioe.2022.1039154
_version_ 1784814986480058368
author Li, Qianru
Liu, Qianqian
Li, Heli
Dong, Liyun
Zhou, Yajie
Zhu, Jintao
Yang, Liu
Tao, Juan
author_facet Li, Qianru
Liu, Qianqian
Li, Heli
Dong, Liyun
Zhou, Yajie
Zhu, Jintao
Yang, Liu
Tao, Juan
author_sort Li, Qianru
collection PubMed
description Nanomedicine has demonstrated great potential in enhancing cancer immunotherapy. However, nanoparticle (NP)-based immunotherapy still has limitations in inducing effective antitumor responses and inhibiting tumor metastasis. Herein, polyethylenimine (PEI) hybrid thin shell hollow mesoporous silica NPs (THMSNs) were applied as adjuvant-nanocarriers and encapsulated with very small dose of photosensitizer chlorine e6 (Ce6) to realize the synergy of photodynamic therapy (PDT)/immunotherapy. Through PEI etching, the obtained Ce6@THMSNs exhibited enhanced cellular internalization and endosome/lysosome escape, which further improved the PDT efficacy of Ce6@THMSNs in destroying tumor cells. After PDT treatment, the released tumor-associated antigens with the help of THMSNs as adjuvants promoted dendritic cells maturation, which further boosted CD8(+) cytotoxic T lymphocytes activation and triggered antitumor immune responses. The in vivo experiments demonstrated the significant potency of Ce6@THMSNs-based PDT in obliterating primary tumors and inducing persistent tumor-specific immune responses, thus preventing distant metastasis. Therefore, we offer a THMSNs-mediated and PDT-triggered nanotherapeutic system with immunogenic property, which can elicit robust antitumor immunity and is promising for future clinical development of immunotherapy.
format Online
Article
Text
id pubmed-9592702
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95927022022-10-26 Modified hollow mesoporous silica nanoparticles as immune adjuvant-nanocarriers for photodynamically enhanced cancer immunotherapy Li, Qianru Liu, Qianqian Li, Heli Dong, Liyun Zhou, Yajie Zhu, Jintao Yang, Liu Tao, Juan Front Bioeng Biotechnol Bioengineering and Biotechnology Nanomedicine has demonstrated great potential in enhancing cancer immunotherapy. However, nanoparticle (NP)-based immunotherapy still has limitations in inducing effective antitumor responses and inhibiting tumor metastasis. Herein, polyethylenimine (PEI) hybrid thin shell hollow mesoporous silica NPs (THMSNs) were applied as adjuvant-nanocarriers and encapsulated with very small dose of photosensitizer chlorine e6 (Ce6) to realize the synergy of photodynamic therapy (PDT)/immunotherapy. Through PEI etching, the obtained Ce6@THMSNs exhibited enhanced cellular internalization and endosome/lysosome escape, which further improved the PDT efficacy of Ce6@THMSNs in destroying tumor cells. After PDT treatment, the released tumor-associated antigens with the help of THMSNs as adjuvants promoted dendritic cells maturation, which further boosted CD8(+) cytotoxic T lymphocytes activation and triggered antitumor immune responses. The in vivo experiments demonstrated the significant potency of Ce6@THMSNs-based PDT in obliterating primary tumors and inducing persistent tumor-specific immune responses, thus preventing distant metastasis. Therefore, we offer a THMSNs-mediated and PDT-triggered nanotherapeutic system with immunogenic property, which can elicit robust antitumor immunity and is promising for future clinical development of immunotherapy. Frontiers Media S.A. 2022-10-11 /pmc/articles/PMC9592702/ /pubmed/36304892 http://dx.doi.org/10.3389/fbioe.2022.1039154 Text en Copyright © 2022 Li, Liu, Li, Dong, Zhou, Zhu, Yang and Tao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Li, Qianru
Liu, Qianqian
Li, Heli
Dong, Liyun
Zhou, Yajie
Zhu, Jintao
Yang, Liu
Tao, Juan
Modified hollow mesoporous silica nanoparticles as immune adjuvant-nanocarriers for photodynamically enhanced cancer immunotherapy
title Modified hollow mesoporous silica nanoparticles as immune adjuvant-nanocarriers for photodynamically enhanced cancer immunotherapy
title_full Modified hollow mesoporous silica nanoparticles as immune adjuvant-nanocarriers for photodynamically enhanced cancer immunotherapy
title_fullStr Modified hollow mesoporous silica nanoparticles as immune adjuvant-nanocarriers for photodynamically enhanced cancer immunotherapy
title_full_unstemmed Modified hollow mesoporous silica nanoparticles as immune adjuvant-nanocarriers for photodynamically enhanced cancer immunotherapy
title_short Modified hollow mesoporous silica nanoparticles as immune adjuvant-nanocarriers for photodynamically enhanced cancer immunotherapy
title_sort modified hollow mesoporous silica nanoparticles as immune adjuvant-nanocarriers for photodynamically enhanced cancer immunotherapy
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592702/
https://www.ncbi.nlm.nih.gov/pubmed/36304892
http://dx.doi.org/10.3389/fbioe.2022.1039154
work_keys_str_mv AT liqianru modifiedhollowmesoporoussilicananoparticlesasimmuneadjuvantnanocarriersforphotodynamicallyenhancedcancerimmunotherapy
AT liuqianqian modifiedhollowmesoporoussilicananoparticlesasimmuneadjuvantnanocarriersforphotodynamicallyenhancedcancerimmunotherapy
AT liheli modifiedhollowmesoporoussilicananoparticlesasimmuneadjuvantnanocarriersforphotodynamicallyenhancedcancerimmunotherapy
AT dongliyun modifiedhollowmesoporoussilicananoparticlesasimmuneadjuvantnanocarriersforphotodynamicallyenhancedcancerimmunotherapy
AT zhouyajie modifiedhollowmesoporoussilicananoparticlesasimmuneadjuvantnanocarriersforphotodynamicallyenhancedcancerimmunotherapy
AT zhujintao modifiedhollowmesoporoussilicananoparticlesasimmuneadjuvantnanocarriersforphotodynamicallyenhancedcancerimmunotherapy
AT yangliu modifiedhollowmesoporoussilicananoparticlesasimmuneadjuvantnanocarriersforphotodynamicallyenhancedcancerimmunotherapy
AT taojuan modifiedhollowmesoporoussilicananoparticlesasimmuneadjuvantnanocarriersforphotodynamicallyenhancedcancerimmunotherapy